Adagene Inc (ADAG)
Adagene Inc. is a clinical-stage biotechnology company focused on discovering, developing, and producing monoclonal antibody therapeutics for cancer. The listed security is an ADR, structured as a depositary receipt representing the company’s common stock on Nasdaq. Adagene’s development pipeline includes several oncology candidates at different stages of clinical and preclinical testing. Its lead program, ADG126, is a masked fully human anti-CTLA-4 monoclonal antibody in phase 1b/2 studies. Other pipeline assets include ADG116 for advanced or metastatic solid tumors, ADG206 for advanced metastatic solid tumors, ADG104, an anti-PD-L1 antibody in phase 2 development, and ADG125, an anti-CSF-1R antibody also in phase 2. The company is additionally advancing preclinical programs such as ADG138, ADG152, ADG153, and CD28 T-cell engager candidates. Adagene was incorporated in 2011 and is headquartered in Suzhou, China.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ADAG
|
$3.57
|
10.5% Upside
|
Fair
|
$9.91
|
206.8% Upside
|
Bargain
|
Fair
|
0.0%
|
December 2, 2026
|
2.4x
|
23.2x
|
216.9 M
|
110.3 M
|
2.5%
|
62.7%
|
2.9
|
94.7%
|
